William Barton Thesis GSK plc (NYSE:GSK) trades at low price multiples relative to competitors. At the surface, it looks like a good buy. However, in my opinion, the lower multiples reflect weaker later stage pipeline relative to competitors. Current pipeline will not face significant patent expirations over the next couple of years, but GSK needs…
Tinnakorn Jorruang/iStock via Getty Images Genmab (GMAB) made a very bold move earlier this month by announcing the acquisition of ProfoundBio for $1.8 billion in cash. The future is never certain, but I really like this acquisition and believe it adds an important piece to Genmab’s technology and drug development platform that was missing –…
J Studios Investment Thesis I think it is safe to say that Pfizer Inc. (NYSE:PFE) is probably one of the least wanted stocks, not only in the pharmaceutical complex of stocks but in the broader view of the market. Pfizer has been plagued by a myriad of issues that are posing severe headwinds for the…
Angelo D’Amico/iStock via Getty Images Pfizer (NYSE:PFE) has had a rough few quarters. Following a massive boom in revenue and profits that was the direct result of the company’s prominent Covid products – including the vaccine (Comirnaty) and Paxlovid – shares have plunged as the pandemic has broadly receded as a global threat: TradingView However,…
metamorworks Cerence (NASDAQ:CRNC) is a leading company in the field of automotive AI assistants. They develop technology that allows drivers to use their voice to control various aspects of their car, such as the navigation system, entertainment system, and climate settings. Their technology is used by many major car manufacturers around the world. Upon its…
Richard Newstead/Moment via Getty Images EVgo (NASDAQ:EVGO) is a leading player in the US electric vehicle / EV charging space, operating a network of over 2,700 fast charging stations with over 785,000 customer accounts as of September 2023. They focus on DC fast charging, which can significantly reduce charging time compared to regular outlets. The…
Caroline Purser/The Image Bank via Getty Images Topline Summary Beam Therapeutics (NASDAQ:BEAM) is biotech with a diversified portfolio of cell and nanoparticle-based therapeutic candidates in its pipeline. They also have a big pool of assets that will carry them for years. But it’s going to take time to come to fruition, and I just don’t…
peterschreiber.media/iStock via Getty Images Topline Summary Prelude Therapeutics Incorporated (NASDAQ:PRLD) is a clinical-stage biopharma developing targeted therapies across a range of different cancers. They have 3 drugs currently in clinical testing, although all of these remain at phase 1 at this time. I have no major concerns about their current cash position, although it might…
fcafotodigital/E+ via Getty Images Coherus BioSciences, Inc. (NASDAQ:CHRS) is a commercial-stage biopharmaceutical company, that markets a few biosimilars and on October 27, 2023, achieved FDA approval of a new drug, Loqtorzi (toripalimab). Further, CHRS saw the approval of a new form of one of its biosimilars, Udenyca Onbody, in December 2023. This article takes a…
pixelfit At a Glance BridgeBio Pharma’s (NASDAQ:BBIO) path has notably shifted. Since my last review, their FDA filing for acoramidis and advancements in cancer treatment, especially for KRAS mutations, are notable. However, financial hurdles are still evident, with a growing net loss and rising shares hinting at possible dilution of shareholder value. Their current ratio…
Andranik Hakobyan Weekly Recap While the calendar was quiet this past week, six IPOs joined the pipeline, two of which we estimate could raise $1 billion or more. Sports equipment and apparel maker Amer Sports (AS) filed to raise an estimated $2 billion. The Finland-based company’s portfolio contains major brands like Arc’teryx, Salomon, Wilson, and…
Chunumunu One small Asian issuer went public in the US this past week, ahead of the Christmas holiday. Japanese e-commerce firm Linkage Global (LGCB) priced at the low end to raise $6 million at an $86 million market cap. Operating through entities in Japan, Hong Kong, and mainland China, Linkage offers a system comprised of…
redtea The past few days have been very busy for Pembina Pipeline Corporation (NYSE:PBA). On December 11th, the management team of the firm came out with initial guidance for the 2024 fiscal year. And two days later, on December 13th, news broke that the company had agreed to acquire the ownership interests that Enbridge Inc….
2d illustrations and photos Just one small IPO priced this past week, joined by one SPAC that began trading. Three IPOs joined the pipeline, including one that plans to raise $100 million, as well as four SPACs. The sole pricing this week was steel framing manufacturer INNO HOLDINGS (INHD), which priced at the low end…
kemalbas My thesis Moderna (NASDAQ:MRNA) stock price has been on a downward trend since the end of 2021 when the Omicron variant appeared, limiting the need for vaccination due to lower severity and greater ability to spread which generated a broader immunity. However, the mRNA purpose should not end with applications restrained to the respiratory…
Kunal Mahto/iStock via Getty Images Gilead Sciences (NASDAQ:GILD) is a $95-billion market cap biopharmaceutical company headquartered in Foster City, California, that specializes in researching, developing, and selling treatments for various medical conditions, including HIV, hepatitis B, hepatitis C, and certain cancers. The company operates in over 35 countries and employs around 17,000 people. In Q2…
Pornpak Khunatorn/iStock via Getty Images At a Glance Kiniksa Pharmaceuticals (NASDAQ:KNSA) finds itself at a pivotal juncture, both clinically and financially. On the clinical front, Arcalyst is rapidly carving out a substantive role in the niche yet significant market of recurrent pericarditis. A 96% risk reduction in recurrence implies not just a revenue stream but…
Studio4/E+ via Getty Images Plains All American Pipeline (NASDAQ:PAA) reported its 2nd quarter earnings with a modest decline quarter over quarter. After updating the 2023 guidance at the top end of the number given during the 4th quarter report, it appears that more distribution increases are on the way. To confirm this, in previous article,…
Sean Anthony Eddy Pharming Group (NASDAQ: NASDAQ:PHAR) stands as a globally recognized biotechnology firm based in the Netherlands. It is best known for its unique approach to addressing rare and genetic diseases. While some may consider their methods unorthodox, their success in the market shows that they are not only viable but also profitable, thus…
muhammet sager While the Mountain Valley Pipeline coming online should be a huge boost to Equitrans Midstream (NYSE:ETRN) moving forward, the benefits already look priced into the stock. Company Profile ETRN is an Appalachia-focused midstream company that operates in three segments: gathering, transmission and water. Former parent EQT (EQT) is its largest customer, representing over…
onurdongel Written by Nick Ackerman. TC Energy Corp. (NYSE:TRP) has certainly been struggling lately with a significant drop in their share price. In fact, it hasn’t only been a recent struggle but more in the last year, as shares are down nearly 37% as of writing. This is a company that has made an appearance…